About us
Meet the Members of Our Pharmaceutical Research Company
Management and Board of Directors
John N. Bonfiglio Ph.D. MBA and has over 30 years of experience in the biotech/pharmaceutical industry, Including over 20 years as a C-level executive in the biotech industry. He is currently a Board member for Avipero and an Executive Board member for Sequella, a US-based biotech company.
Dr. Bonfiglio started his career with 11 years at Allergan pharmaceuticals. Then, I spent three years at Baxter HealthCare before beginning a career in small biotech companies. Finally, I rose to the position of CEO at Peregrine Pharmaceuticals, where he turned around the financially strapped public company.
Dr. Bonfiglio was named COO at Cypress Bioscience while the company was reinventing itself as a neuro-pharmaceutical company. I then joined the Immune Response Corporation as CEO and was responsible for raising over $50M and restarting clinical research in HIV and MS areas.
As CEO at Argos Therapeutics, a privately held oncology company, he raised $35M through a series C financing. His tenure at Argos produced clinical data, which led to an IPO and subsequent financings.
Following Argos, he became President and CEO at Oragenics in Tampa, Fl. I completed two strategic deals with Intrexon Corporation, raised $29M, relisted the company on the NYSE: MKT, and refocused the company on the new novel and proprietary antibiotics.
Dr. Bonfiglio was the COO at TapImmune, where he was responsible for starting a clinical program, raising capital, and relisting the company on Nasdaq. The company is now known as Marker Therapeutics (MRKR -Nasdaq).
Dr. Bonfiglio has held independent Board positions at GT BioPharma (GTBP), Microlin, and Genprex (GNPX).
Bob Marchesani is president and principal consultant with Proventus Consulting LLC. This consulting company guides pharmaceutical and biotechnology companies in the oncology field on integrating prescriber, patient, and payer insights into the drug development process and the commercialization strategy to exceed business goals at launch and beyond.
Marchesani has 33 years of experience in the US and global pharmaceutical industry and has a comprehensive background in product development and brand strategy, international marketing, brand positioning and differentiation, launch strategy, and cross-functional/cross-geographical collaboration.
He demonstrated global brand building, launch excellence, and life-cycle management skills as global brand leader for ALIMTA® (pemetrexed), which achieved peak sales of $2.8 billion, excellent brand equity, and significance as Lilly’s top-selling product in 2014. He also demonstrated launch excellence, leveraging customer insights, and life-cycle management skills as a marketing leader on GEMZAR® (gemcitabine), which achieved peak sales of $1.7 billion in 2008.
And in his last role with Lilly, Marchesani demonstrated strategic product and brand development skills as global brand leader for Lilly’s VERZENIO® (abemaciclib), launched in 2017.
He is a member of the Board of Directors of Isofol Medical AB and a member of the board’s remuneration committee. Marchesani also serves as an adjunct MBA faculty member for the capstone strategy class and as an executive mentor in Butler University’s Lacy School of Business.
He earned an MBA in marketing and a bachelor’s degree in journalism and public relations. Marchesani is a member of the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. He is active in community service and has served in volunteer leadership positions for several educational and community organizations.
https://www.linkedin.com/in/bobmarchesani/
Ian is Chief Medical Officer of Artios Pharma. Ian has a wealth of experience in the translational research and clinical development of medicines to treat cancer.
Prior to joining Artios, Ian has held leadership positions within the global clinical development organizations of both Eli Lilly and Company in the US, and AstraZeneca and has held academic and clinical positions in the University of Aberdeen. He served as Global Senior Medical Director within Lilly he led the worldwide clinical development, regulatory approval and subsequent commercialization of key successful breakthrough medicines for multiple indications. While at AstraZeneca, Ian led both early and late phase clinical development of several novel cancer therapeutics for both adult and pediatric indications.
Ian has served as reviewer for several oncology journals and sat on national grant awarding panels within the United States and the United Kingdom. Prior to joining the pharmaceutical industry Ian was a Clinical Lecturer in the University of Aberdeen where he led research projects evaluating novel methods of predicting and assessing early treatment response of cancer therapeutics.
Nigel has over 25 years experience of working in the city having been a director of Pharmaceutical research at ABN AMRO, First Vice President of Merrill Lynch European Healthcare Equity Research, a partner at Sudbrook Associates, a healthcare corporate advisory business, and a partner at WG Partners. He has a Ph.D. in pharmacology and has worked in the research laboratories of ICI (AstraZeneca) and Glaxo. In addition, he gained Sales and Marketing experience at Glaxo. Nigel has played an active role in a number of the leading corporate transactions, including a number of the major European sector mergers, IPO’s and capital raises.
Was a principal investigator and a senior research fellow at Edinburgh University’s Medical School. She has a long-standing interest in tissue remodeling and repair.
She was trained as a pharmacologist at Bradford University and SmithKline Beechams Cardiopulmonary Product Support Group. She then went on to receive further training and a Ph.D. in matrix remodeling and respiratory function at McGill University’s Meakins Christie Laboratories. She is the principal inventor of the research detailing the use of beta1 integrin in tissue repair and replicative senescence.
Mark brings over 30 years of international leadership experience across biotechnology, global health and medical research. He has built start-ups (2 in biotech), led large, complex organizations through significant change and supported governments and transnational institutions with the development and implementation of policy. He also spent the early part of his career managing humanitarian responses in conflict zones across Africa.
Now he divides his time between a variety of Board roles, Trusteeships, consultancy assignments and mentorship of young entrepreneurs. He also sits on the Audit Committee of the EDCTP, a €2 Billion public-public partnership between Europe and Africa to accelerate the translation of health sector research to public health impact in sub-Saharan Africa.